AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant.
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...
Pfizer's legal win invalidates two GSK patents in UK RSV vaccine case. On Monday, Pfizer Inc. PFE stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro.